AINEWS
FDA cleared Aletta, the first robot authorized to draw blood on its own, citing a phlebotomist shortage, with European patients first in line.
The first robot the FDA has cleared to take over a clinical task wasn't cleared because it outperformed a phlebotomist. It was cleared because the country's phlebotomists are running out.
Aletta, a Dutch-built autonomous blood-draw device, received the agency's first-of-kind authorization on August 19, 2026, and the FDA's own framing names a labor shortage, not a technology breakthrough, as the reason. The math the clearance hangs on: one trained phlebotomist can supervise up to three Aletta machines at the same time. The patients who will see it first are in Europe, not the United States.
That last part is the surprise. Vitestro, the Netherlands-based maker, plans a European rollout first, so U.S. outpatient clinics, the walk-in settings where the clearance actually applies, will wait. The clearance covers adults at those clinics, and it makes the workforce gap the explicit reason a needle-handling device was approved without proving it does the job better than a person.
The device does most of what a phlebotomist's hands would normally do. Once a session is started, the trained phlebotomist stays nearby while Aletta applies the tourniquet, cleans the skin, inserts the needle, swaps tubes, disposes of the needle, and bandages the arm. The phlebotomist verifies tube order and volume afterward. A trained person is still in the room for every draw, but the steady work of placing the needle and managing the tubes now belongs to the machine.
Finding the vein is the step that fails most in human draws, especially on patients whose veins are hard to locate. Aletta scans with near-infrared light and ultrasound to map a usable vein and tell it from an artery. If the scan doesn't find a good vein, the robot stops and waits for a human. The device also keeps the skin wet with disinfectant during the scan, releases the needle and halts the procedure if the patient moves, and carries onboard sensors that can pause the run and alert the supervising phlebotomist. Cleaning between patients is done by hand.
The FDA's stated rationale is the workforce gap. Routine blood work at U.S. outpatient clinics has been getting delayed as trained phlebotomists grow harder to hire, and the agency frames the Aletta authorization as a way to move new technology to patients while preserving safety. That language, labor supply as the reason rather than clinical superiority, sets the device apart from most first-of-kind clearances, which usually arrive after a device proves it beats the existing standard on a clinical outcome.
The clinical case is the part reporters still need to pin down. The FDA decision rests on data the agency says shows the robot hit veins at rates equal to or better than the human baseline. The specific number was not in the agency's press release and was truncated in the re-report coverage that surfaced the story. Trade press covering the clearance, including MedTech Dive and LabMedica, has not published the figure either, so any vein-hit percentage should wait for the FDA's own data or Vitestro's clinical publications before it gets repeated as fact.
What the public record does support: the productivity case is the one the FDA is making. One phlebotomist, three machines, and a procedure that still needs a human nearby but no longer needs human hands on the needle. The first patients in line live in the country where the device was built, not the country that cleared it.